New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2014
08:05 EDTLLYEli Lilly announces positive results of sixth AWARD trial for dulaglutide
Eli Lilly and Company announced positive top-line results of the sixth AWARD trial for once-weekly dulaglutide, an investigational, long-acting glucagon-like peptide 1 receptor agonist being studied as a treatment for type 2 diabetes. In the AWARD-6 study, once-weekly dulaglutide 1.5 mg achieved the primary endpoint of non-inferiority to once-daily liraglutide 1.8 mg, as measured by the reduction of hemoglobin A1c (HbA1c) from baseline at 26 weeks.
News For LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
10:32 EDTLLYFDA approvals Synjardy tablets for adults with Type 2 diabetes
Subscribe for More Information
05:20 EDTLLYEli Lilly, Adocia initiate new Phase 1b study of BioChaperone Lispro
Subscribe for More Information
August 25, 2015
17:11 EDTLLYU.S. District Court rules in Eli Lilly's favor on Alimta vitamin regimen patent
Subscribe for More Information
August 20, 2015
13:26 EDTLLYOn The Fly: Top stock stories at midday
Subscribe for More Information
11:33 EDTLLYLeerink major pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
07:37 EDTLLYEli Lilly's Jardiance for diabetes meets primary endpoint in clinical trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use